Mari L. DeMarco

Papers

Total Citations

H-Index

About

Dr. Mari L. DeMarco is a leading clinical chemist whose work bridges the gap between advanced mass spectrometry and patient care. Her research focuses on developing high-throughput, automated assays for therapeutic drug monitoring, particularly for biologic therapies like infliximab—a monoclonal antibody used to treat Crohn’s disease, ulcerative colitis, and rheumatoid arthritis. Her landmark 2019 paper, "An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab," introduced a novel method to precisely measure drug levels in patients, enabling personalized dosing and improved treatment outcomes. This work, which has garnered over 13 citations, exemplifies her commitment to translating complex analytical chemistry into routine clinical tools. Dr. DeMarco’s contributions are vital for optimizing biologic therapies, reducing adverse effects, and enhancing the quality of life for patients with chronic immune-mediated diseases. Her innovative approach to mass spectrometry-based diagnostics continues to shape the future of precision medicine in clinical laboratories.